Nor Epinephrine

# Nor epinephrine ## Overview - **Classification**: Alpha- and Beta-adrenergic Agonist, Vasopressor, Catecholamine - **Mechanism**: Potently stimulates alpha-1 adrenergic receptors causing vasoconstriction and increased systemic vascular resistance (SVR). Also stimulates beta-1 adrenergic receptors, increasing heart rate and contractility (cardiac output). ## Primary Indications 1. **Acute Hypotension**: Management of profound hypotension in distributive shock (e.g., septic shock). 2. **Cardiogenic Shock**: Used when associated with significant hypotension after adequate fluid resuscitation. 3. **Other Shock States**: Where vasoconstriction is needed to restore adequate perfusion pressure. ## Adult Dosing ### Standard Dosing **Acute Hypotension/Shock** - **Dose**: Initial **0.01-0.03 mcg/kg/min** continuous IV infusion. - **Frequency**: Titrate in increments of **0.005-0.01 mcg/kg/min** every **2-5 minutes** to target BP. - **Route**: Continuous IV infusion via central line. - **Maximum Dose**: Typically up to **0.5 mcg/kg/min**, but higher in refractory shock (e.g., **1-3 mcg/kg/min**). - **Special Considerations**: Dilute in D5W or D5/NS. Avoid NS alone due to stability. ### Dose Adjustments - **Renal Impairment**: No specific dose adjustments; titrate to effect. - **Hepatic Impairment**: No specific dose adjustments; titrate to effect. - **Elderly Patients**: Start at the lower end of the dosing range and titrate cautiously due to increased sensitivity and comorbidities. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: Initial **0.05-0.1 mcg/kg/min** continuous IV infusion. - **Frequency**: Titrate in increments of **0.05 mcg/kg/min** to desired effect. - **Maximum**: Up to **1-2 mcg/kg/min** (higher doses used rarely in refractory cases). - **Special Notes**: Use diluted solutions (e.g., 4 mcg/mL). Monitor closely for end-organ perfusion. ### Infants (1-12 months) - **Dose**: Initial **0.05-0.1 mcg/kg/min** continuous IV infusion. - **Frequency**: Titrate in increments of **0.05 mcg/kg/min** to desired effect. - **Maximum**: Up to **1-2 mcg/kg/min** (higher doses used rarely). ### Children (1-12 years) - **Dose**: Initial **0.05-0.1 mcg/kg/min** continuous IV infusion. - **Frequency**: Titrate in increments of **0.05 mcg/kg/min** to desired effect. - **Maximum**: Up to **1-2 mcg/kg/min** (higher doses used rarely). ### Adolescents (13-18 years) - **Dose**: Follow adult dosing guidelines. - **Maximum**: Adult maximum dose (typically **0.5 mcg/kg/min**, higher in refractory cases). ## Safety Information ### Contraindications - **Absolute**: Hypovolemia (unless adequate fluid resuscitation has occurred). - **Absolute**: Mesenteric or peripheral vascular thrombosis (due to increased ischemia risk). - **Relative**: Cyclopropane or halothane anesthesia (risk of severe arrhythmias). ### Common Adverse Effects - **Very Common (>10%)**: Hypertension, bradycardia (reflex), arrhythmias, anxiety, headache. - **Common (1-10%)**: Peripheral ischemia, renal vasoconstriction/oliguria, hyperglycemia, dyspnea. - **Serious but Rare**: Extravasation leading to tissue necrosis, severe hypertension leading to cerebral hemorrhage, ventricular arrhythmias. ### Key Drug Interactions - **MAOIs (Monoamine Oxidase Inhibitors)**: Potentiation of vasopressor effect, severe hypertension. Avoid concomitant use. - **TCAs (Tricyclic Antidepressants)**: Potentiation of vasopressor effect. Use with caution, consider lower starting dose. - **Alpha-blockers (e.g., Phentolamine)**: Antagonize pressor effect. Phentolamine is used for extravasation. - **Beta-blockers**: Can cause unopposed alpha-stimulation leading to severe hypertension and reflex bradycardia. ## Monitoring & Follow-up - **Before Treatment**: Correct hypovolemia. Assess baseline BP, HR, ECG, electrolytes, renal function. - **During Treatment**: Continuous BP monitoring (arterial line preferred), HR, ECG. - Hourly urine output, lactate, and peripheral perfusion (capillary refill, skin temp). - Monitor central venous pressure (CVP) if available. - **Clinical Signs**: Watch for signs of hypoperfusion (mottling, cool extremities, low urine output), severe hypertension, arrhythmias, chest pain. ## Clinical Pearls - 💡 **Tip 1**: Always administer via a **central venous catheter** to minimize risk of extravasation and tissue necrosis. - 💡 **Tip 2**: If extravasation occurs, immediately infiltrate the affected area with **phentolamine 5-10 mg** diluted in 10-15 mL normal saline. - 💡 **Tip 3**: Titrate to the lowest effective dose to maintain target mean arterial pressure (MAP) to avoid excessive vasoconstriction and end-organ ischemia. - 💡 **Tip 4**: Ensure adequate fluid resuscitation before initiating norepinephrine, as hypovolemia will reduce efficacy and worsen side effects. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.